Shanghai Huaota Biopharmaceutical Co.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Shanghai Huaota Biopharmaceutical Co. sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Shanghai Huaota Biopharmaceutical Co.: 1 sponsored US clinical trial, 1 recruiting.

Shanghai Huaota Biopharmaceutical Co. sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is NSCLC, with 1 trials.

Mid-pack sponsor footprint

Shanghai Huaota Biopharmaceutical Co. is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

What is open in the Shanghai Huaota Biopharmaceutical Co. pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: NSCLC (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Shanghai Huaota Biopharmaceutical Co.: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Shanghai Huaota Biopharmaceutical Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Shanghai Huaota Biopharmaceutical Co.1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Shanghai Huaota Biopharmaceutical Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Shanghai Huaota Biopharmaceutical Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Shanghai Huaota Biopharmaceutical Co. page

1 registered trials is a research-attention snapshot, not an endorsement of Shanghai Huaota Biopharmaceutical Co. or any single study.

  • 1 of Shanghai Huaota Biopharmaceutical Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • NSCLC is the condition Shanghai Huaota Biopharmaceutical Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See NSCLC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Shanghai Huaota Biopharmaceutical Co. pipeline card: 1 registered trials from official public datasets.Report a data error.